ImmuCell Corporation (ICCC) stock price

ImmuCell Corporation (ICCC) is a Healthcare · Biotechnology company listed on NASDAQ. Price $9.95 (-0.30%), Market cap $0.08B, 52-week low–high $4.56 ~ $8.92.

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is masti

Key metrics

Financial statements, price targets, institutional (13F) holdings and related news for ImmuCell Corporation are updated in real time on BlackAll Trade.

ImmuCell Corporation financial summary

Analyst outlook

Key ratios · profitability · growth

Frequently asked questions

What is the current ImmuCell Corporation (ICCC) stock price?

ImmuCell Corporation trades at $9.95 (-0.30%). Real-time quotes and charts are available on BlackAll Trade.

What is the ImmuCell Corporation (ICCC) market cap?

ImmuCell Corporation has a market cap of about $0.08B.

What does ImmuCell Corporation (ICCC) do?

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally.